190 related articles for article (PubMed ID: 16799469)
1. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.
Wang R; Zhang XW; Wang GQ; Chen XC; Tian L; Yang HS; Hu M; Peng F; Yang JL; He QM; Zhang W; Jiang Y; Deng HX; Wen YJ; Li J; Zhao X; Wei YQ
Cancer Gene Ther; 2006 Oct; 13(10):940-7. PubMed ID: 16799469
[TBL] [Abstract][Full Text] [Related]
2. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.
Zhang R; Tian L; Chen LJ; Xiao F; Hou JM; Zhao X; Li G; Yao B; Wen YJ; Li J; Zhang L; Chen XC; Luo F; Peng F; Jiang Y; Wei YQ
Gene Ther; 2006 Sep; 13(17):1263-71. PubMed ID: 16672984
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors.
Li G; Tian L; Hou JM; Ding ZY; He QM; Feng P; Wen YJ; Xiao F; Yao B; Zhang R; Peng F; Jiang Y; Luo F; Zhao X; Zhang L; Zhou Q; Wei YQ
Clin Cancer Res; 2005 Jun; 11(11):4217-24. PubMed ID: 15930360
[TBL] [Abstract][Full Text] [Related]
4. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
Gao ZN; Wei YQ; Yang PS; Xu X; Zhao HQ; Huan X; Kang B
Oral Oncol; 2007 May; 43(5):477-83. PubMed ID: 16997614
[TBL] [Abstract][Full Text] [Related]
6. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
8. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Zhang P; He JB; Ou LW; Wang XH
Ai Zheng; 2006 Apr; 25(4):409-13. PubMed ID: 16613671
[TBL] [Abstract][Full Text] [Related]
9. [Experimental studies on anti-tumor effects of BLC-modified tumor cell vaccine combined with cisplatin].
Zou CH; Tian L; Wei YQ; Zhao X; Kan B; Yang JL; Mao YQ; Wen YJ; Li J; Deng HX
Ai Zheng; 2004 Jan; 23(1):1-7. PubMed ID: 14720366
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
11. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effects of recombinant quail vascular endothelial growth factor receptor 2, as a vaccine, combined with cisplatin on LL/2 tumor model in mice].
Hou JM; Liu JY; Yang L; Zhao X; Tian L; Lei S; Mao YQ; Wen YJ; Wei YQ
Ai Zheng; 2005 Apr; 24(4):391-6. PubMed ID: 15820058
[TBL] [Abstract][Full Text] [Related]
14. Cellular toxic effects of combination of low dose of cisplatin and interstitial injection of 32P glass microspheres on mouse solid tumor S180.
Li WG; Ai H; Chen WL; Jiang LJ; Wu XZ
Chin Med J (Engl); 2005 Jul; 118(13):1099-104. PubMed ID: 16098263
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model.
Luo X; Slater JM; Gridley DS
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):553-64. PubMed ID: 15964154
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
Miyake K; Tsuchida K; Sugino H; Imura S; Morine Y; Fujii M; Shimada M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
[TBL] [Abstract][Full Text] [Related]
18. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
19. Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Yazawa H; Murakami T; Li HM; Back T; Kurosaka K; Suzuki Y; Shorts L; Akiyama Y; Maruyama K; Parsoneault E; Wiltrout RH; Watanabe M
Cancer Gene Ther; 2006 Nov; 13(11):993-1001. PubMed ID: 16763608
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]